FairJourney Biologics Acquires Charles River Laboratories’ South San Francisco Facility to Strengthen Antibody Discovery and Engineering
FairJourney Biologics S.A., a leader in the discovery and optimization of antibodies, has announced the completion of its acquisition of the South San Francisco site from Charles River Laboratories International, Inc. This strategic acquisition aligns with the company’s ongoing growth plan and is set to significantly bolster its antibody discovery and engineering capabilities. It will also strengthen FairJourney’s technology portfolio and expand its global presence with a key biotechnology hub in the United States.
Acquisition of South San Francisco Facility and Proprietary Technologies
The acquisition involves the transfer of ownership of all facilities, staff, and assets from Charles River Laboratories’ South San Francisco site, which was formerly known as Distributed Bio. The deal includes proprietary technologies such as the SuperHuman™, Cosmic™, and Tungsten™ antibody libraries. By integrating these innovative libraries into FairJourney’s existing antibody discovery technologies, the company can offer customers a broader range of antibody discovery tools and introduce new solutions for antibody engineering.
Additionally, FairJourney Biologics will acquire Charles River’s Yeast Display method, which will further expand the company’s antibody discovery platform. This acquisition not only enhances the existing offerings but also provides a comprehensive, state-of-the-art toolkit for discovering and engineering antibodies with precision and efficacy.
Strengthening FairJourney’s Global Presence in Biotechnology Hub
South San Francisco is home to one of the world’s largest biotech clusters, making it an ideal location for expanding FairJourney Biologics’ operations. Establishing a presence in this vibrant biotech hub is a core component of the company’s strategy to enhance its reach and impact in a key global market. The region is known for its concentration of biotechnology companies, research institutions, and talent, making it a critical area for advancing antibody-based technologies.
With the acquisition of the South San Francisco site, FairJourney will be able to provide localized expertise and technical support to customers in the region, accelerating their antibody discovery and engineering pipelines. The new facility also allows FairJourney to collaborate more effectively with leading biotech and pharmaceutical companies, tapping into the region’s industry-leading scientific expertise to promote innovative solutions.
Expanding Capabilities and Offering Advanced Solutions
The South San Francisco site acquisition represents a major step forward for FairJourney Biologics in expanding its capabilities in antibody discovery and optimization. The integration of cutting-edge technologies such as the SuperHuman™, Cosmic™, and Tungsten™ libraries will empower the company to offer its customers a more diverse array of antibody discovery tools. These libraries, known for their high-quality antibody candidates, will enable FairJourney to bring more advanced and efficient antibody engineering solutions to market.
Moreover, the acquisition of the Yeast Display method will strengthen FairJourney’s existing platform, allowing for more refined antibody screening and optimization. This will significantly enhance the company’s ability to identify and engineer antibodies with exceptional specificity and affinity, which are critical factors in developing effective therapeutic and diagnostic antibodies.
Collaboration and Innovation in Antibody Discovery
FairJourney’s acquisition will also foster new opportunities for collaborative projects. By integrating the talented team from Charles River’s South San Francisco site, FairJourney is poised to benefit from the extensive industry expertise of the team, which will help drive forward-thinking antibody discovery initiatives.
The new site will also facilitate collaborative efforts with global biotech and pharmaceutical companies, enabling FairJourney to work closely with industry leaders to bring innovative antibody-based therapies to market. This acquisition strengthens the company’s ability to accelerate R&D and contribute to the development of breakthrough therapies, particularly in areas such as immuno-oncology, autoimmune diseases, and infectious diseases.
CEO Remarks: Strengthening Portfolio and Pushing Boundaries
“We’re pleased to announce this strategic acquisition that will bring the exceptional team at Charles River’s South San Francisco site, as well as their cutting-edge technologies, into FairJourney,” said António Parada, CEO of FairJourney Biologics. “By combining our expertise, we not only strengthen our portfolio with powerful solutions such as the SuperHuman Libraries, but also enhance our ability to deliver innovative solutions to our partners. Working together, we can push the boundaries of antibody discovery and set new industry standards.”
This acquisition represents a significant milestone for FairJourney Biologics, enhancing its competitive edge in the rapidly evolving biotechnology landscape. By combining its existing strengths with the newly acquired technologies and expertise, the company is well-positioned to drive the next wave of antibody discovery and engineering, delivering innovative solutions to meet the global demand for advanced biopharmaceuticals.
Conclusion: A Strategic Move for Future Growth
FairJourney Biologics’ acquisition of the Charles River Laboratories South San Francisco site represents a key strategic move that will not only strengthen its capabilities in antibody discovery and engineering but also expand its global presence in one of the world’s most important biotech hubs. The integration of advanced technologies and the addition of top scientific talent will enable the company to accelerate its growth and deliver cutting-edge antibody-based solutions to customers worldwide. As FairJourney continues to innovate and push the boundaries of antibody discovery, this acquisition positions the company for continued success and leadership in the biotechnology field.
Financial details have not been disclosed.
For more information, please visit: https://fjbio.com/
